Patents by Inventor Steven A. Rosenberg

Steven A. Rosenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION
    Publication number: 20230159614
    Abstract: Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCRs have antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class II molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: February 26, 2021
    Publication date: May 25, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Noam Levin, Rami Yoseph, Biman C. Paria, Steven A. Rosenberg
  • Intracellular genomic transplant and methods of therapy
    Patent number: 11642375
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: May 9, 2023
    Assignees: INTIMA BIOSCIENCE, INC., REGENTS OF THE UNIVERSITY OF MINNESOTA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Branden Moriarity, Beau Webber, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
  • Intracellular genomic transplant and methods of therapy
    Patent number: 11642374
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: May 9, 2023
    Assignees: INTIMA BIOSCIENCE, INC., REGENTS OF THE UNIVERSITY OF MINNESOTA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Branden Moriarity, Beau Webber, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
  • METHODS OF PREPARING ANTI-HUMAN PAPILLOMAVIRUS ANTIGEN T CELLS
    Publication number: 20230139588
    Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
    Type: Application
    Filed: June 13, 2022
    Publication date: May 4, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY
    Publication number: 20230138309
    Abstract: Provided are methods of preparing an enriched population of T cells having antigenic specificity for a target antigen. The method may comprise isolating T cells from a tumor sample of a patient; selecting the isolated T cells which have a gene expression profile; and separating the selected T cells from the unselected cells. The separated selected T cells provide an enriched population of T cells having antigenic specificity for the target antigen. Methods of isolating a T cell receptor (TCR), preparing a population of cells that express a TCR, isolated TCRs, isolated populations of cells, pharmaceutical compositions, and methods of treating or preventing a condition in a mammal are also provided.
    Type: Application
    Filed: March 19, 2021
    Publication date: May 4, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Sri Krishna, Frank J. Lowery, III, Ken-ichi Hanada, James C. Yang, Steven A. Rosenberg, Paul F. Robbins, Rami Yoseph
  • Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
    Patent number: 11629334
    Abstract: Disclosed are methods of isolating T cells and TCRs having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Also disclosed are related methods of preparing a population of cells, populations of cells, TCRs, pharmaceutical compositions, and methods of treating or preventing cancer.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: April 18, 2023
    Assignee: The United States of Americans represented by the Secretary, Department of Health and Human Services
    Inventors: Alena Gros, Steven A. Rosenberg
  • T CELL RECEPTORS RECOGNIZING MHC CLASS II-RESTRICTED MAGE-A3
    Publication number: 20230089465
    Abstract: The invention provides an isolated or purified T-cell receptor (TCR) having antigenic specificity for MHC Class II-restricted MAGE-A3. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a mammal are further provided by the invention.
    Type: Application
    Filed: September 28, 2022
    Publication date: March 23, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Paul F. Robbins, Steven A. Rosenberg, Xin Yao
  • HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION
    Publication number: 20230080742
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with aspartic acid presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: February 12, 2021
    Publication date: March 16, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Noam Levin, Rami Yoseph, Biman Paria, Steven A. Rosenberg
  • HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION
    Publication number: 20230082787
    Abstract: Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCRs have antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided.
    Type: Application
    Filed: February 12, 2021
    Publication date: March 16, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Noam Levin, Maria R. Parkhurst, Frank J. Lowery, III, Steven A. Rosenberg
  • Modified cells and methods of therapy
    Patent number: 11583556
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: February 21, 2023
    Assignees: Regents of the University of Minnesota, Intima Bioscience, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Branden Moriarity, Beau Webber, Modassir Choudhry, R. Scott McIvor, David Largaespada, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
  • HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS
    Publication number: 20230026180
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: September 12, 2022
    Publication date: January 26, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Rami Yoseph, Yong-Chen Lu, Gal Cafri, Steven A. Rosenberg
  • ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS
    Publication number: 20220372103
    Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Application
    Filed: August 1, 2022
    Publication date: November 24, 2022
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY
    Publication number: 20220362297
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Application
    Filed: February 17, 2022
    Publication date: November 17, 2022
    Inventors: Branden MORIARITY, Beau WEBBER, Modasir CHOUDHRY, Steven A. ROSENBERG, Douglas C. PALMER, Nicholas P. RESTIFO
  • Methods of conditioning patients for T cell therapy
    Patent number: 11491187
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: November 8, 2022
    Assignees: Kite Pharma, Inc., The United States of America as Represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
  • T CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN P53
    Publication number: 20220332785
    Abstract: Disclosed are isolated or purified T cell receptors (TCRs) having antigenic specificity for human p53R175H or human p53Y220C. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: June 26, 2020
    Publication date: October 20, 2022
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Drew C. Deniger, Parisa Malekzadeh, Steven A. Rosenberg, Anna Pasetto
  • HLA class I-restricted t cell receptors against mutated RAS
    Patent number: 11466071
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: October 11, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Rami Yoseph, Yong-Chen Lu, Gal Cafri, Steven A. Rosenberg
  • METHODS OF ISOLATING T CELL POPULATIONS
    Publication number: 20220282208
    Abstract: Provided are methods of producing an isolated population of cells for adoptive cell therapy comprising use of at least one cell permeable Ca2+ dye. Further embodiments of the invention provide isolated populations of cells produced by the methods, related pharmaceutical compositions, and related methods of treating or preventing cancer in a patient.
    Type: Application
    Filed: September 18, 2020
    Publication date: September 8, 2022
    Applicant: THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Douglas C. Palmer, Anna Pasetto, Nicholas P. Restifo, Steven A. Rosenberg
  • Anti-human papillomavirus 16 E7 T cell receptors
    Patent number: 11434272
    Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: September 6, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
    Patent number: 11401503
    Abstract: An embodiment of the invention provides a method of promoting regression of cancer in a mammal comprising obtaining a tumor tissue sample from the mammal; culturing the tumor tissue sample in a first gas permeable container containing cell medium therein; obtaining tumor infiltrating lymphocytes (TIL) from the tumor tissue sample; expanding the number of TIL in a second gas permeable container containing cell medium therein using irradiated allogeneic feeder cells and/or irradiated autologous feeder cells; and administering the expanded number of TIL to the mammal. Methods of obtaining an expanded number of TIL from a mammal for adoptive cell immunotherapy are also provided.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: August 2, 2022
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Wilson Wolf Manufacturing Corporation
    Inventors: Steven A. Rosenberg, Mark E. Dudley, David Stroncek, Marianna Sabatino, Jianjian Jin, Robert Somerville, John R. Wilson
  • Writing electronic paper
    Patent number: 11390091
    Abstract: Embodiments of the present invention are directed to systems and methods for writing on electronic paper (“e-paper”) and display platforms implemented with e-paper. In one aspect, a system for writing information to electronic paper includes a writing module and an erasing unit connected to the writing module. The erasing unit is configured to erase information stored in the electronic paper. The system also includes a writing unit connected to the writing module and is configured to write information to the electronic paper. Information is written to the electronic paper by orienting the writing module so that the electronic paper passes the erasing unit prior to passing the writing unit.
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: July 19, 2022
    Assignee: Hewlett-Packard Development Company, L.P.
    Inventors: Omer Gila, Napoleon J. Leoni, Steven Rosenberg, Henryk Birecki